GND-004 (bevacizumab biosimilar) / Noritsu Koki - LARVOL DELTA

Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib (THE ASCO POST) - "Richard S. Finn, MD...discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a front-line phase III study in advanced hepatocellular carcinoma, confirming this combination as the standard of care for patients with previously untreated, unresectable disease (Abstract 267)."

Video

Episode 8: Atezolizumab/Bevacizumab for HCC: Toxicity Management (Targeted Oncology) - "Richard S. Finn, MD: Bevacizumab and the risk of bleeding has always been a concern. What types of patients are considered high risk for bleeding? I don't mean outside of the GI [gastrointestinal] tract. I specifically mean someone who has an endoscopy. Who's at high risk of bleeding?....Catherine Frenette, MD: Patients at high risk for bleeding would include those with large esophageal varices, or large gastric varices....Michael A. Morse, MD, FACP, MHS: I would agree. In general, that's true. Remember, as Catherine pointed out, these are Child-Pugh class A patients who were studied. We don't know what the impact is going to be, frankly, in my practice the more common are the Child-Pugh class B patients."

Video